Association between TCF7L2 polymorphisms and breast cancer susceptibility: a meta-analysis

Our aim was to investigate the relationship between transcription factor 7-like 2 (TCF7L2) polymorphisms and breast cancer susceptibility. PubMed, Embase and CNKI databases were used to search the related studies investigating the correlation between TCF7L2 polymorphisms and breast cancer susceptibi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical and experimental medicine 2015-01, Vol.8 (6), p.9355-9361
Main Authors: Wang, Feng, Jiang, Lixin, Li, Jianlin, Yu, Xiao, Li, Mingchuan, Wu, Guochang, Yu, Zhenyu, Zhou, Kai, Chu, Haidi, Zhai, Huiyuan
Format: Article
Language:English
Subjects:
Original
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 9361
container_issue 6
container_start_page 9355
container_title International journal of clinical and experimental medicine
container_volume 8
creator Wang, Feng
Jiang, Lixin
Li, Jianlin
Yu, Xiao
Li, Mingchuan
Wu, Guochang
Yu, Zhenyu
Zhou, Kai
Chu, Haidi
Zhai, Huiyuan
description Our aim was to investigate the relationship between transcription factor 7-like 2 (TCF7L2) polymorphisms and breast cancer susceptibility. PubMed, Embase and CNKI databases were used to search the related studies investigating the correlation between TCF7L2 polymorphisms and breast cancer susceptibility. Pooled ORs and 95% CIs, based on five genetic models, were applied to estimate the association betweenTCF7L2 polymorphisms and breast cancer. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity. We analyzed six single nucleotide polymorphisms (SNPs) in TCF7L2 gene, namely rs12255372, rs7903146, rs7900150, rs3750805, rs1225404 and rs7003146. The increased risk of breast cancer was associated with TCF7L2 polymorphisms (22 vs. 11: OR=1.16, 95% CI=1.02-1.32; 22+12 vs. 11: OR=1.06, 95% CI=1.02-1.10; 22 vs. 11+12: OR=1.15, 95% CI=1.04-1.27; 2 vs. 1: OR=1.07, 95% CI=1.02-1.13; 12 vs. 11: OR=1.05, 95% CI=1.01-1.09). Among the locus, rs7903146 polymorphism was significantly associated with the risk for breast cancer under five genetic models (TT vs. CC: OR=1.29, 95% CI=1.08-1.53; TT+CT vs. CC: OR=1.09, 95% CI=1.01-1.18; TT vs. CC+CT: OR=1.24, 95% CI=1.05-1.48; T vs. C: OR=1.11, 95% CI=1.04-1.19; CT vs. CC: OR=1.08, 95% CI=1.00-1.17). Additionally, rs7900150 also showed effects on the susceptibility of breast cancer (TT vs. AA: OR=1.22, 95% CI=1.07-1.39; TT+AT vs. AA: OR=1.06, 95% CI=1.00-1.14; TT vs. AA+AT: OR=1.21, 95% CI=1.07-1.37; T vs. A: OR=1.09, 95% CI=1.02-1.15; AT vs. AA: OR=1.04, 95% CI=1.01-1.33). Meanwhile, we found that rs3750805 polymorphism could increased the risk for breast cancer (TT+AT vs. AA: OR=1.12, 95% CI=1.01-1.24). Our meta-analysis demonstrates that TCF7L2 polymorphisms may increase the risk for breast cancer.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4537972</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1708163033</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-53add84b41231f593e2740b440cf366186127f8d408efb9b991292a6106d89fb3</originalsourceid><addsrcrecordid>eNpVkE1LxDAQhoMo7rr6FyRHL4V8NW08CEtxVVjwsl68lEmbupE2qU2q9N9bcJX1NAMzPO_HCVpSJUiSKkJPj_YFugjhnRBJGVfnaMEkJypVcole1yH4ykK03mFt4pcxDu-KTbZluPft1Pmh39vQBQyuxnowECKuwFVmwGEMlemj1ba1cbrFgDsTIQEH7RRsuERnDbTBXB3mCr1s7nfFY7J9fngq1tukZ1LGJOVQ17nQYvZGm1RxwzJBtBCkariUNJ9NZ01eC5KbRiutFGWKgaRE1rlqNF-hux9uP-rO1JVxcYC27AfbwTCVHmz5_-Lsvnzzn6VIeaYyNgNuDoDBf4wmxLKzc7K2BWf8GEqakZzOjXE-v14fa_2J_BbKvwH50nP4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1708163033</pqid></control><display><type>article</type><title>Association between TCF7L2 polymorphisms and breast cancer susceptibility: a meta-analysis</title><source>PubMed Central</source><creator>Wang, Feng ; Jiang, Lixin ; Li, Jianlin ; Yu, Xiao ; Li, Mingchuan ; Wu, Guochang ; Yu, Zhenyu ; Zhou, Kai ; Chu, Haidi ; Zhai, Huiyuan</creator><creatorcontrib>Wang, Feng ; Jiang, Lixin ; Li, Jianlin ; Yu, Xiao ; Li, Mingchuan ; Wu, Guochang ; Yu, Zhenyu ; Zhou, Kai ; Chu, Haidi ; Zhai, Huiyuan</creatorcontrib><description>Our aim was to investigate the relationship between transcription factor 7-like 2 (TCF7L2) polymorphisms and breast cancer susceptibility. PubMed, Embase and CNKI databases were used to search the related studies investigating the correlation between TCF7L2 polymorphisms and breast cancer susceptibility. Pooled ORs and 95% CIs, based on five genetic models, were applied to estimate the association betweenTCF7L2 polymorphisms and breast cancer. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity. We analyzed six single nucleotide polymorphisms (SNPs) in TCF7L2 gene, namely rs12255372, rs7903146, rs7900150, rs3750805, rs1225404 and rs7003146. The increased risk of breast cancer was associated with TCF7L2 polymorphisms (22 vs. 11: OR=1.16, 95% CI=1.02-1.32; 22+12 vs. 11: OR=1.06, 95% CI=1.02-1.10; 22 vs. 11+12: OR=1.15, 95% CI=1.04-1.27; 2 vs. 1: OR=1.07, 95% CI=1.02-1.13; 12 vs. 11: OR=1.05, 95% CI=1.01-1.09). Among the locus, rs7903146 polymorphism was significantly associated with the risk for breast cancer under five genetic models (TT vs. CC: OR=1.29, 95% CI=1.08-1.53; TT+CT vs. CC: OR=1.09, 95% CI=1.01-1.18; TT vs. CC+CT: OR=1.24, 95% CI=1.05-1.48; T vs. C: OR=1.11, 95% CI=1.04-1.19; CT vs. CC: OR=1.08, 95% CI=1.00-1.17). Additionally, rs7900150 also showed effects on the susceptibility of breast cancer (TT vs. AA: OR=1.22, 95% CI=1.07-1.39; TT+AT vs. AA: OR=1.06, 95% CI=1.00-1.14; TT vs. AA+AT: OR=1.21, 95% CI=1.07-1.37; T vs. A: OR=1.09, 95% CI=1.02-1.15; AT vs. AA: OR=1.04, 95% CI=1.01-1.33). Meanwhile, we found that rs3750805 polymorphism could increased the risk for breast cancer (TT+AT vs. AA: OR=1.12, 95% CI=1.01-1.24). Our meta-analysis demonstrates that TCF7L2 polymorphisms may increase the risk for breast cancer.</description><identifier>ISSN: 1940-5901</identifier><identifier>EISSN: 1940-5901</identifier><identifier>PMID: 26309596</identifier><language>eng</language><publisher>United States: e-Century Publishing Corporation</publisher><subject>Original</subject><ispartof>International journal of clinical and experimental medicine, 2015-01, Vol.8 (6), p.9355-9361</ispartof><rights>IJCEM Copyright © 2015 2015</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537972/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537972/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26309596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Feng</creatorcontrib><creatorcontrib>Jiang, Lixin</creatorcontrib><creatorcontrib>Li, Jianlin</creatorcontrib><creatorcontrib>Yu, Xiao</creatorcontrib><creatorcontrib>Li, Mingchuan</creatorcontrib><creatorcontrib>Wu, Guochang</creatorcontrib><creatorcontrib>Yu, Zhenyu</creatorcontrib><creatorcontrib>Zhou, Kai</creatorcontrib><creatorcontrib>Chu, Haidi</creatorcontrib><creatorcontrib>Zhai, Huiyuan</creatorcontrib><title>Association between TCF7L2 polymorphisms and breast cancer susceptibility: a meta-analysis</title><title>International journal of clinical and experimental medicine</title><addtitle>Int J Clin Exp Med</addtitle><description>Our aim was to investigate the relationship between transcription factor 7-like 2 (TCF7L2) polymorphisms and breast cancer susceptibility. PubMed, Embase and CNKI databases were used to search the related studies investigating the correlation between TCF7L2 polymorphisms and breast cancer susceptibility. Pooled ORs and 95% CIs, based on five genetic models, were applied to estimate the association betweenTCF7L2 polymorphisms and breast cancer. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity. We analyzed six single nucleotide polymorphisms (SNPs) in TCF7L2 gene, namely rs12255372, rs7903146, rs7900150, rs3750805, rs1225404 and rs7003146. The increased risk of breast cancer was associated with TCF7L2 polymorphisms (22 vs. 11: OR=1.16, 95% CI=1.02-1.32; 22+12 vs. 11: OR=1.06, 95% CI=1.02-1.10; 22 vs. 11+12: OR=1.15, 95% CI=1.04-1.27; 2 vs. 1: OR=1.07, 95% CI=1.02-1.13; 12 vs. 11: OR=1.05, 95% CI=1.01-1.09). Among the locus, rs7903146 polymorphism was significantly associated with the risk for breast cancer under five genetic models (TT vs. CC: OR=1.29, 95% CI=1.08-1.53; TT+CT vs. CC: OR=1.09, 95% CI=1.01-1.18; TT vs. CC+CT: OR=1.24, 95% CI=1.05-1.48; T vs. C: OR=1.11, 95% CI=1.04-1.19; CT vs. CC: OR=1.08, 95% CI=1.00-1.17). Additionally, rs7900150 also showed effects on the susceptibility of breast cancer (TT vs. AA: OR=1.22, 95% CI=1.07-1.39; TT+AT vs. AA: OR=1.06, 95% CI=1.00-1.14; TT vs. AA+AT: OR=1.21, 95% CI=1.07-1.37; T vs. A: OR=1.09, 95% CI=1.02-1.15; AT vs. AA: OR=1.04, 95% CI=1.01-1.33). Meanwhile, we found that rs3750805 polymorphism could increased the risk for breast cancer (TT+AT vs. AA: OR=1.12, 95% CI=1.01-1.24). Our meta-analysis demonstrates that TCF7L2 polymorphisms may increase the risk for breast cancer.</description><subject>Original</subject><issn>1940-5901</issn><issn>1940-5901</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkE1LxDAQhoMo7rr6FyRHL4V8NW08CEtxVVjwsl68lEmbupE2qU2q9N9bcJX1NAMzPO_HCVpSJUiSKkJPj_YFugjhnRBJGVfnaMEkJypVcole1yH4ykK03mFt4pcxDu-KTbZluPft1Pmh39vQBQyuxnowECKuwFVmwGEMlemj1ba1cbrFgDsTIQEH7RRsuERnDbTBXB3mCr1s7nfFY7J9fngq1tukZ1LGJOVQ17nQYvZGm1RxwzJBtBCkariUNJ9NZ01eC5KbRiutFGWKgaRE1rlqNF-hux9uP-rO1JVxcYC27AfbwTCVHmz5_-Lsvnzzn6VIeaYyNgNuDoDBf4wmxLKzc7K2BWf8GEqakZzOjXE-v14fa_2J_BbKvwH50nP4</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Wang, Feng</creator><creator>Jiang, Lixin</creator><creator>Li, Jianlin</creator><creator>Yu, Xiao</creator><creator>Li, Mingchuan</creator><creator>Wu, Guochang</creator><creator>Yu, Zhenyu</creator><creator>Zhou, Kai</creator><creator>Chu, Haidi</creator><creator>Zhai, Huiyuan</creator><general>e-Century Publishing Corporation</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>Association between TCF7L2 polymorphisms and breast cancer susceptibility: a meta-analysis</title><author>Wang, Feng ; Jiang, Lixin ; Li, Jianlin ; Yu, Xiao ; Li, Mingchuan ; Wu, Guochang ; Yu, Zhenyu ; Zhou, Kai ; Chu, Haidi ; Zhai, Huiyuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-53add84b41231f593e2740b440cf366186127f8d408efb9b991292a6106d89fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Wang, Feng</creatorcontrib><creatorcontrib>Jiang, Lixin</creatorcontrib><creatorcontrib>Li, Jianlin</creatorcontrib><creatorcontrib>Yu, Xiao</creatorcontrib><creatorcontrib>Li, Mingchuan</creatorcontrib><creatorcontrib>Wu, Guochang</creatorcontrib><creatorcontrib>Yu, Zhenyu</creatorcontrib><creatorcontrib>Zhou, Kai</creatorcontrib><creatorcontrib>Chu, Haidi</creatorcontrib><creatorcontrib>Zhai, Huiyuan</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Feng</au><au>Jiang, Lixin</au><au>Li, Jianlin</au><au>Yu, Xiao</au><au>Li, Mingchuan</au><au>Wu, Guochang</au><au>Yu, Zhenyu</au><au>Zhou, Kai</au><au>Chu, Haidi</au><au>Zhai, Huiyuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between TCF7L2 polymorphisms and breast cancer susceptibility: a meta-analysis</atitle><jtitle>International journal of clinical and experimental medicine</jtitle><addtitle>Int J Clin Exp Med</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>8</volume><issue>6</issue><spage>9355</spage><epage>9361</epage><pages>9355-9361</pages><issn>1940-5901</issn><eissn>1940-5901</eissn><abstract>Our aim was to investigate the relationship between transcription factor 7-like 2 (TCF7L2) polymorphisms and breast cancer susceptibility. PubMed, Embase and CNKI databases were used to search the related studies investigating the correlation between TCF7L2 polymorphisms and breast cancer susceptibility. Pooled ORs and 95% CIs, based on five genetic models, were applied to estimate the association betweenTCF7L2 polymorphisms and breast cancer. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity. We analyzed six single nucleotide polymorphisms (SNPs) in TCF7L2 gene, namely rs12255372, rs7903146, rs7900150, rs3750805, rs1225404 and rs7003146. The increased risk of breast cancer was associated with TCF7L2 polymorphisms (22 vs. 11: OR=1.16, 95% CI=1.02-1.32; 22+12 vs. 11: OR=1.06, 95% CI=1.02-1.10; 22 vs. 11+12: OR=1.15, 95% CI=1.04-1.27; 2 vs. 1: OR=1.07, 95% CI=1.02-1.13; 12 vs. 11: OR=1.05, 95% CI=1.01-1.09). Among the locus, rs7903146 polymorphism was significantly associated with the risk for breast cancer under five genetic models (TT vs. CC: OR=1.29, 95% CI=1.08-1.53; TT+CT vs. CC: OR=1.09, 95% CI=1.01-1.18; TT vs. CC+CT: OR=1.24, 95% CI=1.05-1.48; T vs. C: OR=1.11, 95% CI=1.04-1.19; CT vs. CC: OR=1.08, 95% CI=1.00-1.17). Additionally, rs7900150 also showed effects on the susceptibility of breast cancer (TT vs. AA: OR=1.22, 95% CI=1.07-1.39; TT+AT vs. AA: OR=1.06, 95% CI=1.00-1.14; TT vs. AA+AT: OR=1.21, 95% CI=1.07-1.37; T vs. A: OR=1.09, 95% CI=1.02-1.15; AT vs. AA: OR=1.04, 95% CI=1.01-1.33). Meanwhile, we found that rs3750805 polymorphism could increased the risk for breast cancer (TT+AT vs. AA: OR=1.12, 95% CI=1.01-1.24). Our meta-analysis demonstrates that TCF7L2 polymorphisms may increase the risk for breast cancer.</abstract><cop>United States</cop><pub>e-Century Publishing Corporation</pub><pmid>26309596</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1940-5901
ispartof International journal of clinical and experimental medicine, 2015-01, Vol.8 (6), p.9355-9361
issn 1940-5901
1940-5901
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4537972
source PubMed Central
subjects Original
title Association between TCF7L2 polymorphisms and breast cancer susceptibility: a meta-analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T13%3A34%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20TCF7L2%20polymorphisms%20and%20breast%20cancer%20susceptibility:%20a%20meta-analysis&rft.jtitle=International%20journal%20of%20clinical%20and%20experimental%20medicine&rft.au=Wang,%20Feng&rft.date=2015-01-01&rft.volume=8&rft.issue=6&rft.spage=9355&rft.epage=9361&rft.pages=9355-9361&rft.issn=1940-5901&rft.eissn=1940-5901&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1708163033%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p266t-53add84b41231f593e2740b440cf366186127f8d408efb9b991292a6106d89fb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1708163033&rft_id=info:pmid/26309596&rfr_iscdi=true